FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Leslie Citrome

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Activities & Behaviors

Procedures

Double-Blind Method

Co-author Network

Publications

TOP 3
Leslie Citrome; T A Ketter
When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Leslie Citrome
Review: limited evidence on effects of haloperidol alone for rapid tranquillisation in psychosis-induced aggression.
Joseph P McEvoy; Andrei Pikalov; Leslie Citrome; Josephine Cucchiaro; David Hernandez; Jay Hsu; Antony Loebel
Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Leslie Citrome (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Leslie Citrome; T A Ketter
When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
International journal of clinical practice 2013;67(5):407-11.
2013: Leslie Citrome
Review: limited evidence on effects of haloperidol alone for rapid tranquillisation in psychosis-induced aggression.
Evidence-based mental health 2013;16(2):47.
2013: Joseph P McEvoy; Andrei Pikalov; Leslie Citrome; Josephine Cucchiaro; David Hernandez; Jay Hsu; Antony Loebel
Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
The Journal of clinical psychiatry 2013;74(2):170-9.
2013: Leslie Citrome
Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
Advances in therapy 2013;30(2):114-26.
2013: Leslie Citrome
Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy.
Advances in therapy 2013;30(2):102-13.
2013: Leslie Citrome
Cariprazine : chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
Expert opinion on drug metabolism & toxicology 2013;9(2):193-206.
2012: Amy Weiss-Citrome; Leslie Citrome
Antidepressant therapy for pain associated with osteoarthritis.
PM & R : the journal of injury, function, and rehabilitation 2012;4(12):1024-5.
2012: T A Ketter; Leslie Citrome
Addressing challenges in bipolar diagnosis: what do good clinicians already do? An editorial comment to Phelps J, Ghaemi SN 'The mistaken claim of bipolar 'overdiagnosis': solving the false positives problem for DSM-5/ICD-11'.
Acta psychiatrica Scandinavica 2012;126(6):393-4.
2012: Leslie Citrome
Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.
CNS spectrums 2012;17 Suppl 1():1-9.
2012: Leslie Citrome
Lurasidone in schizophrenia: new information about dosage and place in therapy.
Advances in therapy 2012;29(10):815-25.
2012: Leslie Citrome; Henry A Nasrallah
On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.
Expert opinion on pharmacotherapy 2012;13(11):1599-613.
2012: Leslie Citrome
A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.
Expert opinion on pharmacotherapy 2012;13(11):1545-73.
2012: Leslie Citrome
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Clinical schizophrenia & related psychoses 2012;6(2):76-85.
2012: Leslie Citrome
Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.
Expert opinion on drug metabolism & toxicology 2012;8(7):873-88.
2012: Leslie Citrome
Impact of the CATIE trial on antipsychotic prescribing.
Schizophrenia research 2012;138(2-3):295.
2012: Leslie Citrome; Josephine Cucchiaro; Debra Phillips; Kaushik Sarma; Robert Silva; Satoru Tsuchiya; Antony Loebel
Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.
International clinical psychopharmacology 2012;27(3):165-76.
2012: Leslie Citrome
Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
International journal of clinical practice 2012;66(4):356-68.
2012: Leslie Citrome; Robert A Forbes; Zhenchao Guo; Iftekhar Kalsekar; Tony Hebden
Trends in combination antipsychotic use among persons with commercial insurance: a data snapshot.
Innovations in clinical neuroscience 2012;9(3):17-8.
2012: Joshua T Kantrowitz; Leslie Citrome
Lurasidone for schizophrenia: what's different?
Expert review of neurotherapeutics 2012;12(3):265-73.
2012: Leslie Citrome
Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
International journal of clinical practice 2012;66(3):318-25.
2012: Leslie Citrome; Amy Weiss-Citrome
A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Postgraduate medicine 2012;124(1):83-93.
2012: Leslie Citrome; Marla Hochfeld; Xiangyi Meng; Stephen M Stahl
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Human psychopharmacology 2012;27(1):24-32.
2011: Leslie Citrome; Jan Volavka
Pharmacological management of acute and persistent aggression in forensic psychiatry settings.
CNS drugs 2011;25(12):1009-21.
2011: Leslie Citrome
Olanzapine-fluoxetine combination for the treatment of bipolar depression.
Expert opinion on pharmacotherapy 2011;12(17):2751-8.
2011: Leslie Citrome
Treatment-resistant schizophrenia: what's next.
Schizophrenia research 2011;133(1-3):1-2.
2011: Peter F Buckley; Leslie Citrome; Elena Carmen Nichita; Michael Vitacco
Psychopharmacology of aggression in schizophrenia.
Schizophrenia bulletin 2011;37(5):930-6.
2011: Leslie Citrome; Xiangyi Meng; Marla Hochfeld
Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
Schizophrenia research 2011;131(1-3):75-81.
2011: Jan Volavka; Leslie Citrome
Pathways to aggression in schizophrenia affect results of treatment.
Schizophrenia bulletin 2011;37(5):921-9.
2011: Leslie Citrome
Evidence-based medicine: it's not just about the evidence.
International journal of clinical practice 2011;65(6):634-5.
2011: Leslie Citrome
Drug safety evaluation of ziprasidone.
Expert opinion on drug safety 2011;10(3):437-48.
2011: Jean-Pierre Lindenmayer; Leslie Citrome; Anzalee Khan; Sashank Kaushik; Saurabh Kaushik
A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder.
Journal of clinical psychopharmacology 2011;31(2):160-8.
2011: Joshua T Kantrowitz; Leslie Citrome
Schizoaffective disorder: a review of current research themes and pharmacological management.
CNS drugs 2011;25(4):317-31.
2011: Leslie Citrome
Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Postgraduate medicine 2011;123(2):153-62.
2011: Leslie Citrome
Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it.
The Journal of clinical psychiatry 2011;72(3):412-3.
2011: Leslie Citrome
Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder.
International journal of clinical practice 2011;65(3):330-40.
2011: Terence A Ketter; Leslie Citrome; P W Wang; J L Culver; S Srivastava
Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?
Acta psychiatrica Scandinavica 2011;123(3):175-89.
2011: Leslie Citrome
Likelihood to be helped or harmed can assist in clinical decision-making.
The Journal of clinical psychiatry 2011;72(2):261-2; author reply 262.
2011: Leslie Citrome
Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
International journal of clinical practice 2011;65(2):189-210.
2011: Fabien Trémeau; Cristina J Mauro; Constance Shope; Leah M Riber; Surjit Dhami; Leslie Citrome
High dose quetiapine in the treatment of psychosis due to traumatic brain injury: a case report.
Progress in neuro-psychopharmacology & biological psychiatry 2011;35(1):280-1.
2011: Leslie Citrome
Role of sublingual asenapine in treatment of schizophrenia.
Neuropsychiatric disease and treatment 2011;7():325-39.
2011: Leslie Citrome; Richard I G Holt; Daniel J Walker; Vicki Poole Hoffmann
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
Clinical drug investigation 2011;31(7):455-82.
2011: Leslie Citrome
Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
Clinical schizophrenia & related psychoses 2011;4(4):251-7.
2010: Jeff Ventimiglia; Amir H Kalali; Leslie Citrome
A review of new atypical antipsychotic launches in the United States.
Psychiatry (Edgmont (Pa. : Township)) 2010;7(12):13-5.
2010: Leslie Citrome
Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.
Expert opinion on drug metabolism & toxicology 2010;6(12):1551-64.
2010: Nadine Revheim; William M Greenberg; Leslie Citrome
Spirituality, schizophrenia, and state hospitals: program description and characteristics of self-selected attendees of a spirituality therapeutic group.
The Psychiatric quarterly 2010;81(4):285-92.
2010: Leslie Citrome
Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
International journal of clinical practice 2010;64(11):1462-5.
2010: Peter Dussias; Amir Kalali; Leslie Citrome
Polypharmacy of schizophrenia.
Psychiatry (Edgmont (Pa. : Township)) 2010;7(8):17-9.
2010: Leslie Citrome
Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Postgraduate medicine 2010;122(4):39-48.
2010: Leslie Citrome
Nine out of ten doctors prefer Camels! Three brief essays regarding how we use and abuse statistics.
International journal of clinical practice 2010;64(8):997-8.
2010: Leslie Citrome
Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults.
Expert review of neurotherapeutics 2010;10(7):1031-7.
2010: Joshua T Kantrowitz; Erin Oakman; Stephan Bickel; Leslie Citrome; Arthur Spielman; Gail Silipo; Joseph Battaglia; Daniel C Javitt
The importance of a good night's sleep: an open-label trial of the sodium salt of gamma-hydroxybutyric acid in insomnia associated with schizophrenia.
Schizophrenia research 2010;120(1-3):225-6.
2010: Leslie Citrome; Ari Jaffe; Jerome Levine
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Schizophrenia research 2010;119(1-3):153-9.
2010: Leslie Citrome
Evidence-based flying: a new paradigm for frequent flyers.
International journal of clinical practice 2010;64(6):667-8.
2010: Leslie Citrome
Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic.
International journal of clinical practice 2010;64(6):707-18.
2010: Leslie Citrome; Stuart V Moss
How to efficiently maintain your own electronic resource library.
The Journal of clinical psychiatry 2010;71(2):207-8.
2010: Leslie Citrome
Relative vs. absolute measures of benefit and risk: what's the difference?
Acta psychiatrica Scandinavica 2010;121(2):94-102.
2010: Gareen Hamalian; Leslie Citrome
Stimulant-induced trichotillomania.
Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 2010;31(1):68-70.
2010: Leslie Citrome
Citability of original research and reviews in journals and their sponsored supplements.
PloS one 2010;5(3):e9876.
2010: Leslie Citrome; Ari Jaffe; Jerome Levine
Datapoints: depot antipsychotic use in New York State hospitals, 1994 to 2009.
Psychiatric services (Washington, D.C.) 2010;61(1):9.
2010: Leslie Citrome
Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.
International journal of clinical practice 2010;64(2):216-39.
2009: Leslie Citrome; Christopher Reist; Liisa Palmer; Leslie B Montejano; Gregory Lenhart; Brian Cuffel; James Harnett; Kafi N Sanders
Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder.
Schizophrenia research 2009;115(2-3):115-20.
2009: Leslie Citrome
Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
International journal of clinical practice 2009;63(12):1762-84.
2009: Leslie Citrome; Menahem Krakowski
The impact of ethnicity on metabolic outcomes during treatment with antipsychotics: complexities abound.
The Journal of clinical psychiatry 2009;70(11):1608-9.
2009: Leslie Citrome; S V Moss; C Graf
How to search and harvest the medical literature: let the citations come to you, and how to proceed when they do.
International journal of clinical practice 2009;63(11):1565-70.
2009: Leslie Citrome
Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications.
Current drug safety 2009;4(3):229-37.
2009: Karen A Nolan; Constance B Shope; Leslie Citrome; Jan Volavka
Staff and patient views of the reasons for aggressive incidents: a prospective, incident-based study.
The Psychiatric quarterly 2009;80(3):167-72.
2009: Leslie Citrome
Using oral ziprasidone effectively: the food effect and dose-response.
Advances in therapy 2009;26(8):739-48.
2009: Leslie Citrome
Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
International journal of clinical practice 2009;63(8):1237-48.
2009: Joshua Kantrowitz; Leslie Citrome; Daniel Javitt
GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications.
CNS drugs 2009;23(8):681-91.
2009: Jan Volavka; Leslie Citrome
Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
Expert opinion on pharmacotherapy 2009;10(12):1917-28.
2009: Leslie Citrome; Ari Jaffe; Jerome Levine
How dosing of ziprasidone in a state hospital system differs from product labeling.
The Journal of clinical psychiatry 2009;70(7):975-82.
2009: Leslie Citrome; Joshua T Kantrowitz
Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?
Expert review of neurotherapeutics 2009;9(7):1045-58.
2009: Jean-Pierre Lindenmayer; Hong Liu-Seifert; Pandurang M Kulkarni; Bruce J Kinon; Virginia L Stauffer; Sara E Edwards; Lei Chen; David H Adams; Haya Ascher-Svanum; Peter F Buckley; Leslie Citrome; Jan Volavka
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.
The Journal of clinical psychiatry 2009;70(7):990-6.
2009: Joshua T Kantrowitz; Leslie Citrome; Daniel C Javitt
A review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia.
Clinical therapeutics 2009;31 Pt 1():1360-73.
2009: Leslie Citrome
Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility?
The Journal of clinical psychiatry 2009;70(6):932-3.
2009: Leslie Citrome
Systematic reviews: much ado about a lot.
International journal of clinical practice 2009;63(6):832-3.
2009: Leslie Citrome; Richard I G Holt
Egg consumption and risk of type 2 diabetes in men and women: response to Djoussé et al.
Diabetes care 2009;32(6):e73; author reply e74.
2009: Leslie Citrome; Virginia L Stauffer; Lei Chen; Bruce J Kinon; Darcie L Kurtz; Jennie G Jacobson; Richard F Bergstrom
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.
Journal of clinical psychopharmacology 2009;29(3):278-83.
2009: Leslie Citrome; Ruoyong Yang; Paul Glue; Onur N Karayal
Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
Schizophrenia research 2009;111(1-3):39-45.
2009: Ari Jaffe; Jerome Levine; Leslie Citrome
"Stat" medication administration predicts hospital discharge.
The Psychiatric quarterly 2009;80(2):65-73.
2009: Menahem I Krakowski; Pal Czobor; Leslie Citrome
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
Schizophrenia research 2009;110(1-3):95-102.
2009: Jan Volavka; Leslie Citrome
All antipsychotics are equal, but some are more equal than others.
The Journal of clinical psychiatry 2009;70(3):429-30.
2009: Leslie Citrome; T A Ketter
Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions.
International journal of clinical practice 2009;63(3):353-9.
2009: Leslie Citrome; Christopher Reist; Liisa Palmer; Leslie Montejano; Greg Lenhart; Brian Cuffel; James Harnett; Kafi N Sanders
Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder.
Schizophrenia research 2009;108(1-3):238-44.
2009: Leslie Citrome
Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.
Patient preference and adherence 2009;3():345-55.
2009: Leslie Citrome
Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.
International journal of clinical practice 2009;63(1):140-50.
2008: Leslie Citrome
Show me the evidence: now what do I do with it?
Southern medical journal 2008;101(12):1197.
2008: Joshua T Kantrowitz; Leslie Citrome
Olanzapine: review of safety 2008.
Expert opinion on drug safety 2008;7(6):761-9.
2008: Fabien Trémeau; Michelle Goggin; Daniel Antonius; Pal Czobor; Vera Hill; Leslie Citrome
A new rating scale for negative symptoms: the Motor-Affective-Social Scale.
Psychiatry research 2008;160(3):346-55.
2008: Leslie Citrome; Henry Epstein; Karen A Nolan; Fabien Trémeau; Charles Elin; Biman Roy; Jerome Levine
Public-academic partnerships: integrating state psychiatric hospital treatment and clinical research.
Psychiatric services (Washington, D.C.) 2008;59(9):958-60.
2008: Bruce J Kinon; Jan Volavka; Virginia Stauffer; Sara E Edwards; Hong Liu-Seifert; Lei Chen; David H Adams; Jean-Pierre Lindenmayer; Joseph P McEvoy; Peter F Buckley; Jeffrey A Lieberman; Herbert Y Meltzer; Daniel R. Wilson; Leslie Citrome
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
Journal of clinical psychopharmacology 2008;28(4):392-400.
2008: Leslie Citrome
Valproate: do formulations matter?
Journal of clinical pharmacy and therapeutics 2008;33(4):457; author reply 458.
2008: Jan Volavka; Leslie Citrome
Heterogeneity of violence in schizophrenia and implications for long-term treatment.
International journal of clinical practice 2008;62(8):1237-45.
2008: Fabien Trémeau; Melissa Brady; Erica Saccente; Alexis Moreno; Henry Epstein; Leslie Citrome; Dolores Malaspina; Daniel Javitt
Loss aversion in schizophrenia.
Schizophrenia research 2008;103(1-3):121-8.
2008: Leslie Citrome; Betty Vreeland
Schizophrenia, obesity, and antipsychotic medications: what can we do?
Postgraduate medicine 2008;120(2):18-33.
2008: Leslie Citrome; Joshua Kantrowitz
Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.
Expert review of neurotherapeutics 2008;8(7):1079-91.
2008: Leslie Citrome
Compelling or irrelevant? Using number needed to treat can help decide.
Acta psychiatrica Scandinavica 2008;117(6):412-9.
2008: Karen A Nolan; Leslie Citrome
Reducing inpatient aggression: does paying attention pay off?
The Psychiatric quarterly 2008;79(2):91-5.
2008: Leslie Citrome; Ari Jaffe; David Martello; Baerbel Allingham; Jerome Levine
Did CATIE influence antipsychotic use?
Psychiatric services (Washington, D.C.) 2008;59(5):476.
2008: Robert C Peveler; David Branford; Leslie Citrome; Peter Fitzgerald; Philip W Harvey; Richard Holt; Louise Howard; Dora Kohen; Ian Jones; Veronica O'Keane; Carmine M Pariente; John Pendlebury; Shubulade M Smith; David Yeomans
Antipsychotics and hyperprolactinaemia: clinical recommendations.
Journal of psychopharmacology (Oxford, England) 2008;22(2 Suppl):98-103.
2008: Leslie Citrome
Current guidelines and their recommendations for prolactin monitoring in psychosis.
Journal of psychopharmacology (Oxford, England) 2008;22(2 Suppl):90-7.
2008: Serdar M Dursun; Hiram Joseph Wildgust; Paul Strickland; Guy M Goodwin; Leslie Citrome; Mike Lean
The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness.
Journal of psychopharmacology (Oxford, England) 2008;22(2 Suppl):3-5.
2008: Joshua Kantrowitz; Leslie Citrome
Paliperidone: the evidence of its therapeutic value in schizophrenia.
Core evidence 2008;2(4):261-71.
2007: Leslie Citrome
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.
The Journal of clinical psychiatry 2007;68(12):1876-85.
2007: Donald C Goff; Richard Keefe; Leslie Citrome; Katherine Davy; John H Krystal; Charles Large; Thomas R Thompson; Jan Volavka; Elizabeth Webster
Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials.
Journal of clinical psychopharmacology 2007;27(6):582-9.
2007: Leslie Citrome; Constance B Shope; Karen A Nolan; Pal Czobor; Jan Volavka
Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.
International clinical psychopharmacology 2007;22(6):356-62.
2007: Leslie Citrome
Interpreting and Applying the CATIE Results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T.
Psychiatry (Edgmont (Pa. : Township)) 2007;4(10):23-9.
2007: Leslie Citrome
Atypical antipsychotics, elderly patients, and mortality risk.
Southern medical journal 2007;100(10):964-5.
2007: Jamie Karagianis; Michael Rosenbluth; Mauricio Tohen; Haya Ascher-Svanum; Tamas Treuer; Maurício Silva de Lima; Leslie Citrome
Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools.
Current medical research and opinion 2007;23(10):2551-7.
2007: Leslie Citrome; Richard Holt; Woodie M Zachry; Jerry D Clewell; Paul A Orth; Jamie Karagianis; Vicki Poole Hoffmann
Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.
The Annals of pharmacotherapy 2007;41(10):1593-603.
2007: Leslie Citrome
Show me the evidence: using number needed to treat.
Southern medical journal 2007;100(9):881-4.
2007: Leslie Citrome
Interventions for the treatment of acute agitation.
CNS spectrums 2007;12(8 Suppl 11):8-12.
2007: Elisa F Cascade; Amir Kalali; Leslie Citrome
Antipsychotic use varies by patient age.
Psychiatry (Edgmont (Pa. : Township)) 2007;4(7):20-3.
2007: Leslie Citrome; Jean-Paul Macher; Daniel E Salazar; Suresh Mallikaarjun; David W Boulton
Pharmacokinetics of aripiprazole and concomitant carbamazepine.
Journal of clinical psychopharmacology 2007;27(3):279-83.
2007: Leslie Citrome
Impact factor? Shmimpact factor!: the journal impact factor, modern day literature searching, and the publication process.
Psychiatry (Edgmont (Pa. : Township)) 2007;4(5):54-7.
2007: Glenn W Currier; Leslie Citrome; Dan L Zimbroff; Dan A Oren; George Manos; Robert D McQuade; Andrei Pikalov; David T Crandall
Intramuscular aripiprazole in the control of agitation.
Journal of psychiatric practice 2007;13(3):159-69.
2007: Leslie Citrome
The psychopharmacology of violence with emphasis on schizophrenia, part 2: long-term treatment.
The Journal of clinical psychiatry 2007;68(2):331-2.
2007: Leslie Citrome
The effectiveness criterion: balancing efficacy against the risks of weight gain.
The Journal of clinical psychiatry 2007;68 Suppl 12():12-7.
2007: Leslie Citrome
Introduction: weighing the evidence: weight management insights for treating major mental illness.
The Journal of clinical psychiatry 2007;68 Suppl 12():4.
2007: William M Greenberg; Leslie Citrome
Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.
CNS drug reviews 2007;13(2):137-77.
2007: Leslie Citrome
The psychopharmacology of violence with emphasis on schizophrenia, part 1: acute treatment.
The Journal of clinical psychiatry 2007;68(1):163-4.
2007: Leslie Citrome; Ari Jaffe; Jerome Levine
Datapoints: The ups and downs of dosing second-generation antipsychotics.
Psychiatric services (Washington, D.C.) 2007;58(1):11.
2006: Leslie Citrome
A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder.
Neuropsychiatric disease and treatment 2006;2(4):427-43.
2006: Bruce J Kinon; Hong Liu-Seifert; David H Adams; Leslie Citrome
Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Journal of clinical psychopharmacology 2006;26(6):632-7.
2006: William M Glazer; Robert R Conley; Leslie Citrome
Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study.
CNS spectrums 2006;11(9 Suppl 10):1-13; quiz 14.
2006: Leslie Citrome; Ari Jaffe; Jerome Levine; David Martello
Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004.
Psychiatric services (Washington, D.C.) 2006;57(8):1132-9.
2006: Leslie Citrome
Maintenance treatment with olanzapine reduces relapse in people with bipolar I disorder who have responded to acute olanzapine treatment.
Evidence-based mental health 2006;9(3):73.
2006: Menahem I Krakowski; Pal Czobor; Leslie Citrome; Nigel Bark; Thomas B Cooper
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Archives of general psychiatry 2006;63(6):622-9.
2006: Karen A Nolan; Pal Czobor; Leslie Citrome; Menachem Krakowski; Herbert M Lachman; James L Kennedy; Xingqun Ni; Jeffrey Lieberman; Miranda Chakos; Jan Volavka
Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics.
Journal of clinical psychopharmacology 2006;26(3):338-40.
2006: Ilya Lipkovich; Leslie Citrome; Roy H Perlis; Walter Deberdt; John P Houston; Jonna Ahl; Thomas A Hardy
Early predictors of substantial weight gain in bipolar patients treated with olanzapine.
Journal of clinical psychopharmacology 2006;26(3):316-20.
2006: Leslie Citrome; Jan Volavka; Pal Czobor; Shlomo Brook; Antony Loebel; Francine S Mandel
Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.
The Journal of clinical psychiatry 2006;67(4):638-42.
2006: Matthew Hoptman; Jan Volavka; Pal Czobor; Guido Gerig; Miranda Chakos; Joseph Blocher; Leslie Citrome; Brian Sheitman; Jean-Pierre Lindenmayer; Jeffrey A Lieberman; Robert Bilder
Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder.
The Journal of neuropsychiatry and clinical neurosciences 2006;18(4):509-15.
2006: Leslie Citrome; Richard Holt; Timothy G Dinan
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al.
Diabetes care 2006;29(1):176; author reply 177-8.
2005: Leslie Citrome; Ari Jaffe; Jerome Levine; Jean-Pierre Lindenmayer
Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies.
The Journal of clinical psychiatry 2005;66(12):1512-6.
2005: Matthew Hoptman; Jan Volavka; Elisabeth M Weiss; Pal Czobor; Philip Szeszko; Guido Gerig; Miranda Chakos; Joseph Blocher; Leslie Citrome; Jean-Pierre Lindenmayer; Brian Sheitman; Jeffrey A Lieberman; Robert Bilder
Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder.
Psychiatry research 2005;140(2):133-45.
2005: Jan Volavka; Pal Czobor; Leslie Citrome; Robert D McQuade; William H Carson; Dusan Kostic; Sterling Hardy; Ronald Marcus
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
The Journal of clinical psychiatry 2005;66(11):1362-6.
2005: Leslie Citrome; David Yeomans
Do guidelines for severe mental illness promote physical health and well-being?
Journal of psychopharmacology (Oxford, England) 2005;19(6 Suppl):102-9.
2005: Leslie Citrome
Metabolic syndrome and cardiovascular disease.
Journal of psychopharmacology (Oxford, England) 2005;19(6 Suppl):84-93.
2005: Richard Holt; Chris Bushe; Leslie Citrome
Diabetes and schizophrenia 2005: are we any closer to understanding the link?
Journal of psychopharmacology (Oxford, England) 2005;19(6 Suppl):56-65.
2005: Daniel J Müller; Vincenzo De Luca; Tricia Sicard; Nicole King; Rudi Hwang; Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy
Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2005;15(5):525-31.
2005: Dan L Zimbroff; Michael Allen; John Battaglia; Leslie Citrome; Avrim Fishkind; Andrew Francis; Daniel Herr; Douglas Hughes; Marc Martel; Horacio Preval; Ruth Ross
Best clinical practice with ziprasidone IM: update after 2 years of experience.
CNS spectrums 2005;10(9):1-15.
2005: Leslie Citrome; Jan Volavka
Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement.
The Journal of clinical psychiatry 2005;66(8):1073-4.
2005: Leslie Citrome; Ari Jaffe; Jerome Levine
Dosing of second-generation antipsychotic medication in a state hospital system.
Journal of clinical psychopharmacology 2005;25(4):388-91.
2005: Leslie Citrome; Lawrence Blonde; Cristina Damatarca
Metabolic issues in patients with severe mental illness.
Southern medical journal 2005;98(7):714-20.
2005: Jan Volavka; Karen A Nolan; Linda Kline; Pal Czobor; Leslie Citrome; Brian Sheitman; Jean-Pierre Lindenmayer; Joseph McEvoy; Jeffrey A Lieberman
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Schizophrenia research 2005;76(1):127-9.
2005: Leslie Citrome
Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitus.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2005;8(2):147-51.
2005: Daniel J Müller; Tim Klempan; Vincenzo De Luca; Tricia Sicard; Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Jeffrey A Lieberman; William Honer; James L Kennedy
The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.
Neuroscience letters 2005;379(2):81-9.
2005: Vincenzo De Luca; John B Vincent; Daniel J Müller; Rudi Hwang; Takahiro Shinkai; Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Jeffrey A Lieberman; James L Kennedy
Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment.
Pharmacological research : the official journal of the Italian Pharmacological Society 2005;51(4):381-4.
2005: Leslie Citrome
Antipsychotic medication and diabetes mellitus.
The Journal of clinical psychiatry 2005;66(3):395; author reply 395.
2005: Leslie Citrome; Ari Jaffe; Jerome Levine
Monotherapy versus polypharmacy for hospitalized psychiatric patients.
The American journal of psychiatry 2005;162(3):631; author reply 632-3.
2005: Leslie Citrome; Joseph Goldberg
Commentary: bipolar disorder is a potentially fatal disease.
Postgraduate medicine 2005;117(2):9-11.
2005: Joseph F Goldberg; Leslie Citrome
Latest therapies for bipolar disorder. Looking beyond lithium.
Postgraduate medicine 2005;117(2):25-6, 29-32, 35-6.
2005: Leslie Citrome; Joseph F Goldberg
The many faces of bipolar disorder. How to tell them apart.
Postgraduate medicine 2005;117(2):15-6, 19-23.
2005: Leslie Citrome; Joseph F Goldberg; Stephen M Stahl
Toward convergence in the medication treatment of bipolar disorder and schizophrenia.
Harvard review of psychiatry 2005;13(1):28-42.
2005: Leslie Citrome; Richard Josiassen; Nigel Bark; Daniel E Salazar; Suresh Mallikaarjun
Pharmacokinetics of aripiprazole and concomitant lithium and valproate.
Journal of clinical pharmacology 2005;45(1):89-93.
2005: Karen A Nolan; Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Jeffrey A Lieberman
Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.
Journal of psychiatric research 2005;39(1):109-15.
2004: Leslie Citrome; Jan Volavka
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Postgraduate medicine 2004;116(4):49-51, 55-9, 63.
2004: Leslie Citrome; Ari Jaffe; Jerome Levine; Baerbel Allingham; James Robinson
Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.
Psychiatric services (Washington, D.C.) 2004;55(9):1006-13.
2004: Leslie Citrome; Jan Volavka
Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement.
Diabetes care 2004;27(8):2087-8; author reply 2089-90.
2004: Leslie Citrome
Re: treatment noncompliance with orally disintegrating olanzapine tablets.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 2004;49(6):412-3; author reply 413.
2004: Leslie Citrome; Fabien Tremeau; Pe Shein Wynn; Biman Roy; Hassan Dinakar
A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia.
Journal of clinical psychopharmacology 2004;24(3):255-9.
2004: Jan Volavka; James L Kennedy; Xingqun Ni; Pal Czobor; Karen A Nolan; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Jeffrey A Lieberman
COMT158 polymorphism and hostility.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2004;127B(1):28-9.
2004: Leslie Citrome
The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents.
Drugs of today (Barcelona, Spain : 1998) 2004;40(5):445-64.
2004: Jan Volavka; Pal Czobor; Karen A Nolan; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Jeffrey A Lieberman
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Journal of clinical psychopharmacology 2004;24(2):225-8.
2004: Jean-Pierre Lindenmayer; Pal Czobor; Jan Volavka; Jeffrey A Lieberman; Leslie Citrome; Brian Sheitman; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
The Journal of clinical psychiatry 2004;65(4):551-6.
2004: Jan Volavka; Leslie Citrome
Olanzapine vs haloperidol for treatment of schizophrenia.
JAMA : the journal of the American Medical Association 2004;291(9):1064; author reply 1065-6.
2004: Leslie Citrome; Daniel E Casey; David G Daniel; Patricia Wozniak; Lisa D Kochan; Katherine A Tracy
Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.
Psychiatric services (Washington, D.C.) 2004;55(3):290-4.
2004: Leslie Citrome
Flexible oral olanzapine dosing in acutely agitated people is immediately effective in reducing symptoms.
Evidence-based mental health 2004;7(1):12.
2004: Leslie Citrome
New treatments for agitation.
The Psychiatric quarterly 2004;75(3):197-213.
2004: Jan Volavka; Pal Czobor; Thomas B Cooper; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Jeffrey A Lieberman
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
The Journal of clinical psychiatry 2004;65(1):57-61.
2003: Leslie Citrome; Ari B Jaffe
Relationship of atypical antipsychotics with development of diabetes mellitus.
The Annals of pharmacotherapy 2003;37(12):1849-57.
2003: Karen A Nolan; Pal Czobor; Biman B Roy; Meredith M Platt; Constance B Shope; Leslie Citrome; Jan Volavka
Characteristics of assaultive behavior among psychiatric inpatients.
Psychiatric services (Washington, D.C.) 2003;54(7):1012-6.
2003: Mary Ann Richardson; Margaret L Bevans; Laura L Read; Helen M Chao; James D Clelland; Raymond F Suckow; Timothy J Maher; Leslie Citrome
Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.
The American journal of psychiatry 2003;160(6):1117-24.
2003: Jean-Pierre Lindenmayer; Pal Czobor; Jan Volavka; Leslie Citrome; Brian Sheitman; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
The American journal of psychiatry 2003;160(2):290-6.
2003: Leslie Citrome
Efficacy should drive atypical antipsychotic treatment.
BMJ (Clinical research ed.) 2003;326(7383):283.
2003: Leslie Citrome
Schizophrenia and valproate.
Psychopharmacology bulletin 2003;37 Suppl 2():74-88.
2002: Fabien Trémeau; Leslie Citrome
Optimizing dosing in atypical neuroleptic monotherapy.
Dialogues in clinical neuroscience 2002;4(4):438-43.
2002: Leslie Citrome
Atypical antipsychotics for acute agitation. New intramuscular options offer advantages.
Postgraduate medicine 2002;112(6):85-8, 94-6.
2002: Jean-Pierre Lindenmayer; Pal Czobor; Jan Volavka; Jeffrey A Lieberman; Leslie Citrome; Brian Sheitman; Miranda Chakos; Joseph P McEvoy
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
The Journal of clinical psychiatry 2002;63(10):931-5.
2002: Robert Bilder; Jan Volavka; Pal Czobor; Anil Malhotra; James L Kennedy; Xingqun Ni; Robert S Goldman; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Jeffrey A Lieberman
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia.
Biological psychiatry 2002;52(7):701-7.
2002: Leslie Citrome; Ari Jaffe; Jerome Levine; Baerbel Allingham
Use of mood stabilizers among patients with schizophrenia, 1994-2001.
Psychiatric services (Washington, D.C.) 2002;53(10):1212.
2002: Leslie Citrome; Jan Volavka
Optimal dosing of atypical antipsychotics in adults: a review of the current evidence.
Harvard review of psychiatry 2002;10(5):280-91.
2002: Leslie Citrome; Robert Bilder; Jan Volavka
Managing treatment-resistant schizophrenia: evidence from randomized clinical trials.
Journal of psychiatric practice 2002;8(4):205-15.
2002: Robert Bilder; Robert S Goldman; Jan Volavka; Pal Czobor; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Terri L Horowitz; Jeffrey A Lieberman
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
The American journal of psychiatry 2002;159(6):1018-28.
2002: Pal Czobor; Jan Volavka; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Antipsychotic-induced weight gain and therapeutic response: a differential association.
Journal of clinical psychopharmacology 2002;22(3):244-51.
2002: Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
The American journal of psychiatry 2002;159(2):255-62.
2002: Leslie Citrome; Jan Volavka
Atypical antipsychotics: revolutionary or incremental advance?
Expert review of neurotherapeutics 2002;2(1):69-88.
2001: Leslie Citrome; Menahem I Krakowski; William M Greenberg; E Andrade; Jan Volavka
Antiaggressive effect of quetiapine in a patient with schizoaffective disorder.
The Journal of clinical psychiatry 2001;62(11):901.
2001: Leslie Citrome; Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Joseph McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Psychiatric services (Washington, D.C.) 2001;52(11):1510-4.
2001: Jean-Pierre Lindenmayer; Jan Volavka; J Lieberman; Brian Sheitman; Leslie Citrome; Miranda Chakos; Pal Czobor; B Parker; Adel Iskander
Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
Journal of clinical psychopharmacology 2001;21(4):448-53.
2000: Leslie Citrome; Jerome Levine; Baerbel Allingham
Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.
Psychiatric services (Washington, D.C.) 2000;51(5):634-8.
2000: Jan Volavka; Thomas B Cooper; Pal Czobor; Jean-Pierre Lindenmayer; Leslie Citrome; Pavel Mohr; Nigel Bark
High-dose treatment with haloperidol: the effect of dose reduction.
Journal of clinical psychopharmacology 2000;20(2):252-6.
1998: Leslie Citrome
Safety of Accutane with possible depression.
Postgraduate medicine 1998;104(4):38.
1998: Leslie Citrome; Jerome Levine; Baerbel Allingham
Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health.
The Psychiatric quarterly 1998;69(4):283-300.
1998: Leslie Citrome
Practice protocols, parameters, pathways, and guidelines: a review.
Administration and policy in mental health 1998;25(3):257-69.
1997: Leslie Citrome
Layoffs, reductions-in-force, downsizing, rightsizing: the case of a state psychiatric hospital.
Administration and policy in mental health 1997;24(6):523-33.
1995: Leslie Citrome
Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital.
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 1995;11(2):55-9.